Effect of P2Y12 Inhibitors, SGLT2 Inhibitors and P-Selectin Inhibitors on One-year Quality-of-Life Outcomes in Critically Ill Patients Hospitalized for COVID-19: A Pre-specified Secondary Analysis of the ACTIV4a Randomized Clinical Trial
Moha Asri Abdullah, Joshua Froess, Jeffrey S. Berger, Mark W. Geraci et autres